Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Links With Alibaba And Tencent In China 'Digital Health' Push

Executive Summary

AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.

You may also be interested in...



Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.

Managing Expectations: "We're Still On Target" Says AstraZeneca CEO

Pascal Soriot says AstraZeneca remains on track to hit its $45bn sales target in 2023 – more or less - but to do that the UK's second biggest drug maker must maintain recent improvements in R&D productivity.

AstraZeneca's Pangalos On How He Turned Around R&D Productivity

As head of AstraZeneca's global research and early development arms Menelas Pangalos has, in the space of eight years, boosted AstraZeneca's pipeline productivity from below industry average to one of the best, at a fraction of the cost. He talked to Scrip about how he effected this transformation using his "5R" framework, and what he needs to do next.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel